Received Feb 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | G97Y2 | — |
second dose was given 01/14/2025; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too long in a 75-year-old male patient who received Herpes zoster (Shingrix) (batch number G97Y2, expiry date 19-MAY-2031) for prophylaxis. Previously administered products included Shingrix (The first dose was given 07-SEP-2019). On 14-JAN-2025, the patient received the 2nd dose of Shingrix. On 14-JAN-2025, 1956 days after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: second dose was given 01/14/2025). The outcome of the drug dose administration interval too long was unknown. Additional Information: GSK Receipt Date: 18-FEB-2025 A pharmacy student contacted to request information about the validity of a second dose of Shingrix that was administered years after the initial dose. The first dose was given 07-SEP-2019, no other information was given and second dose was given 14-JAN-2025 which led to drug dose administration interval too long. The reporter consented to follow up. The Vaccine Administration Facility is the same as Primary Reporter.